Transcode Therapeutics Inc (NASDAQ:RNAZ) — Market Cap & Net Worth
Market Cap & Net Worth: Transcode Therapeutics Inc (RNAZ)
Transcode Therapeutics Inc (NASDAQ:RNAZ) has a market capitalization of $7.18 Million ($7.18 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27625 globally and #5462 in its home market, demonstrating a -9.69% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Transcode Therapeutics Inc's stock price $7.83 by its total outstanding shares 916968 (916.97K). Analyse Transcode Therapeutics Inc cash conversion from operations to see how efficiently the company converts income to cash.
Transcode Therapeutics Inc Market Cap History: 2021 to 2026
Transcode Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows change from $1.86 Billion to $7.18 Million (-71.30% CAGR).
Index Memberships
Transcode Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #808 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2611 of 3165 |
Weight: Transcode Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Transcode Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Transcode Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RNAZ by Market Capitalization
Companies near Transcode Therapeutics Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Transcode Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Transcode Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Transcode Therapeutics Inc's market cap moved from $1.86 Billion to $ 7.18 Million, with a yearly change of -71.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $7.18 Million | +14.64% |
| 2025 | $6.26 Million | +102.67% |
| 2024 | $3.09 Million | -48.94% |
| 2023 | $6.05 Million | -98.77% |
| 2022 | $493.70 Million | -73.50% |
| 2021 | $1.86 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Transcode Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.18 Million USD |
| MoneyControl | $7.18 Million USD |
| MarketWatch | $7.18 Million USD |
| marketcap.company | $7.18 Million USD |
| Reuters | $7.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its… Read more